Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors?
Saved in:
| Published in: | Journal of Diabetes Investigation |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1868847780230856705 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Journal of Diabetes Investigation |
| description | |
| discipline_display | Hematology |
| discipline_facet | Hematology |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:95040 |
| institution | FRELIP |
| journal_source_facet | Journal of Diabetes Investigation |
| last_indexed | 2026-06-24T03:35:28.979Z |
| publishDate | 2026 |
| publishDateSort | 2026 |
| record_format | rss_article |
| spellingShingle | Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors? Hematology General Hematology |
| sub_discipline_display | General |
| sub_discipline_facet | General |
| subject_display | Hematology General Hematology |
| subject_facet | Hematology General Hematology |
| title | Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors? |
| title_alt | ¿Los factores de selección de tratamiento enfatizados en las guías clínicas (enfermedad renal crónica, enfermedad cardiovascular e insuficiencia cardíaca) contribuyen al riesgo de infecciones del tracto urinario durante la administración de inhibidores del cotransportador de sodio-glucosa tipo 2? Les facteurs de sélection du traitement mis en avant dans les directives cliniques—maladie rénale chronique, maladie cardiovasculaire et insuffisance cardiaque—contribuent-ils au risque d'infections urinaires lors de l'administration d'inhibiteurs du cotransporteur sodium-glucose de type 2 ? Os fatores de seleção de tratamento enfatizados nas diretrizes clínicas—doença renal crônica, doença cardiovascular e insuficiência cardíaca—contribuem para o risco de infecções do trato urinário durante a administração de inibidores do cotransportador sódio-glicose 2? |
| title_auth | Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors? |
| title_es_txt | ¿Los factores de selección de tratamiento enfatizados en las guías clínicas (enfermedad renal crónica, enfermedad cardiovascular e insuficiencia cardíaca) contribuyen al riesgo de infecciones del tracto urinario durante la administración de inhibidores del cotransportador de sodio-glucosa tipo 2? |
| title_fr_txt | Les facteurs de sélection du traitement mis en avant dans les directives cliniques—maladie rénale chronique, maladie cardiovasculaire et insuffisance cardiaque—contribuent-ils au risque d'infections urinaires lors de l'administration d'inhibiteurs du cotransporteur sodium-glucose de type 2 ? |
| title_full | Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors? |
| title_fullStr | Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors? |
| title_full_unstemmed | Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors? |
| title_pt_txt | Os fatores de seleção de tratamento enfatizados nas diretrizes clínicas—doença renal crônica, doença cardiovascular e insuficiência cardíaca—contribuem para o risco de infecções do trato urinário durante a administração de inibidores do cotransportador sódio-glicose 2? |
| title_short | Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors? |
| title_sort | do the treatment selection factors emphasized in clinical guidelines—chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors? |
| topic | Hematology General Hematology |
| url | https://onlinelibrary.wiley.com/doi/10.1111/jdi.70362?af=R |